RHFI
VNDA icon

Reilly Herbert Faulkner III’s Vanda Pharmaceuticals VNDA Stock Holding History

Reilly Herbert Faulkner III’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$300K Hold
20,000
– – 0.1% 50
2020
Q4 		$263K Hold
20,000
– – 0.09% 51
2020
Q3 		$193K Buy
+20,000
New +$214K 0.07% 52

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Reilly Herbert Faulkner III's VNDA Position: Q1 2021 in Review

Reilly Herbert Faulkner III held its Vanda Pharmaceuticals (VNDA) position steady in Q1 2021 at 20,000 shares worth $300K. The position accounts for 0.1% of the portfolio, ranked #50.

Reilly Herbert Faulkner III first reported a position in VNDA in Q3 2020 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold VNDA as of Q1 2021.

  • Reilly Herbert Faulkner III held 20,000 shares of Vanda Pharmaceuticals worth $300K as of Q1 2021.
  • Reilly Herbert Faulkner III left its Vanda Pharmaceuticals share count unchanged in Q1 2021.
  • Vanda Pharmaceuticals made up 0.1% of Reilly Herbert Faulkner III's portfolio in Q1 2021, its #50 holding.
  • Reilly Herbert Faulkner III first reported a position in Vanda Pharmaceuticals in Q3 2020 and has held it in 3 quarters since.
  • 189 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2021.

Based on Reilly Herbert Faulkner III's 13F filing for Q1 2021, filed 12 May 2021.